ป้ายกำกับ: lecanemab
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass […]
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe
TOKYO, Jan 11, 2023 ̵ […]
Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
TOKYO, Sep 28, 2022 ̵ […]
Eisai Presents New Findings on Lecanemab’s Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
TOKYO and CAMBRIDGE, Mass […]
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
TOKYO, Jun 22, 2022 ̵ […]
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
CAMBRIDGE, Mass., and TOK […]
Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments
CAMBRIDGE, Mass., and TOK […]
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference
TOKYO and CAMBRIDGE, Mass […]
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension
TOKYO, Nov 11, 2021 ̵ […]
Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
TOKYO, Nov 4, 2021 – […]
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
TOKYO, Jul 30, 2021 ̵ […]
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
TOKYO, Jun 24, 2021 ̵ […]